The Prostate Biospecimen Core of this Specialized Program of Research Excellence (SPORE) provides a coordinated, centralized and dedicated program for procurement and processing of biospecimens obtained from men with prostate cancer. Human biospecimens are one of the most valuable and unique resources available for translational at Mayo Clinic, Rochester. Mayo Clinic's goal of the Biospecimen Core is to collect spectrum of biospecimens tissue, blood and urine, from every prostate cancer patient undergoing treatment for their disease. Biospecimen Core will coordinate acquisition of normal and neoplastic prostate tissues, blood and urine for translational research. A portion of normal and prostate cancer tissue from each patient will be obtained fresh and stored frozen to provide investigators with DMA and RNA and the remainder of the tissue will be available in paraffin blocks stored at the Mayo Clinic Tissue Registry. The Biospecimen Core will serve as a resource of expertise, collaborative effort and service for pathology, immunohistochemistry, in situ hybridization, laser capture microdissection, reverse-transcriptase polymerase chain reaction (RT-PCR), tissue microarrays and digital image analysis (DIA). The Biospecimen Core will provide an interface and be electronically integrated with the Prostate Cancer Patient Registry, Biostatistics Core and the CaBIG initiative. The collection, banking and use of biospecimens will be performed with appropriate patient consent, state and institutional approval. The Biospecimen Core will interact and collaborate with other Prostate SPOREs to promote resource sharing and integrate scientific projects of mutual interest.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091956-09
Application #
7919522
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
9
Fiscal Year
2009
Total Cost
$217,845
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ahmed, Kamran A; Davis, Brian J; Mynderse, Lance A et al. (2014) Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol 9:171
Wu, Qiang; Kohli, Manish; Bergen 3rd, H Robert et al. (2014) Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther 13:1067-77

Showing the most recent 10 out of 206 publications